The Center for Applied Genomics focuses on the genetic and genomic research with an emphasis on next-generation sequencing (NGS). Work at the Center for Applied Genomics ranges from basic research to diagnostics, drug discovery and applications to public health.
We provide high quality Next-Generation (Next-Gen) sequencing data, quickly, and at a reasonable cost.
Email us to request an information packet
Index of Services
Our facility offers state-of-the-art, Next-Gen services utilizing the 454 GS-FLX+ Titanium™, sequencing platform, which can be used in support of your research projects. We specialize in sequencing genes from pooled amplicons of immunogenetic complexes, including the human leukocyte antigen (HLA), and genes involved in cardiomyopathies. By utilizing amplicon-based Next-Gen technologies, we can provide provide fast and economical genomic research sequence support for immunogenomics, disease association, pharmacogenetics, population genetics and personalized medicine studies.
Our services include, but are not limited to:
- HLA amplicon sequencing services - allelic typing to 6-8 digit resolution of class I and II genes (HLA-A, HLA-B, HLA-C, DRB1/3/4/5, DQB1, DQA1, DPB1, DPA1 in any combination of multiple or single genes)
- KIR amplicon sequencing services – allelic typing of all KIR loci, including all exons and some upstream and intronic regions (available Spring 2013)
- Genes involved in cardiomyopathies: NKX2-5, ISL1, MEF2C, GATA4, GATA5, GATA6, ZFPM2, FOXH1, FGF8, CRKL
- Ultra deep sequencing providing highly sensitive detection levels without any bias
- Expertise Using Roche GS FLX+ for long reads
- Custom amplicon sequencing services (call to discuss)
- Quality data and reasonable rates and turnaround time
Our amplicon sequencing is based on ultra deep sequencing of PCR products, and can be used for analyzing genetic variations within a population. The long read lengths and data accuracy of Roche GS FLX+ makes the technology the gold standard for amplicon sequencing. As each molecule within a pool of amplicons can be sequenced individually, the technology has the power to detect rare variants with detection limits of at least 0.5 percent.